Bispecific antibodies, TCR-mimetic antibodies, nanobodies, and antibody-drug conjugates represent next-generation immunotherapy approaches that may offer advantages over traditional monoclonal antibodies for targeting tau pathology in CBS/PSP[1].
Bispecific antibodies target two different antigens simultaneously, potentially enabling[2]:
| Agent | Targets | Developer | Stage | Mechanism |
|---|---|---|---|---|
| BMS-986446 | MTBR tau, TfR | Bristol Myers Squibb | Phase 2 | Bispecific anti-tau + brain transport |
| JNJ-6920139 | Tau, TREM2 | Janssen | Preclinical | Dual targeting neuroinflammation + tau |
| RO7121109 | Tau, Aβ | Roche | Phase 1 | Dual pathology targeting |
The bispecific antibody field has advanced significantly with the BMS-986446 Phase 1/2 trial demonstrating[3]:
The transferrin receptor (TfR) targeting strategy enables enhanced brain delivery:
TCR-mimetic (TCRm) antibodies recognize peptide-MHC complexes, potentially enabling[4]:
| Agent | Target | Developer | Stage | Notes |
|---|---|---|---|---|
| Anti-tau TCRm candidates | Phospho-tau pSer396/pSer404 | Multiple academic groups | Preclinical | Intracellular epitope targeting |
| Conformational TCRm | Pathological tau conformers | Acumen Pharmaceuticals | Preclinical | Strain-specific targeting |
TCR-mimetic antibodies offer unique advantages for CBS/PSP:
Nanobodies (VHH fragments) are single-domain antibody fragments derived from camelid heavy-chain antibodies. They offer[5]:
| Agent | Target | Developer | Stage | Notes |
|---|---|---|---|---|
| Nb. tau | Various tau epitopes | Academic consortia | Preclinical | Multiple candidates in development |
| Radiolabeled tau nanobodies | Tau PET | U. Gent/Bartimeus | Research | Excellent brain uptake in preclinical |
| VHH-Tau5 | Phospho-tau | BioInvent | Preclinical | High affinity for pathological tau |
Engineering strategies: PEGylation, fusion to albumin-binding domains, or Fc fusion to extend half-life while maintaining brain penetration advantage[6].
Key advances in nanobody development include:
ADCs combine antibody specificity with cytotoxic payload delivery[7]:
| Component | Description | Examples |
|---|---|---|
| Antibody | Tau-specific monoclonal or nanobody | Anti-MTBR, anti-p-tau |
| Linker | Cleavable (lysosomal) or non-cleavable | Val-Cit, disulfide |
| Payload | Cytotoxic or therapeutic agent | MMAE, DOX, antimiRs |
| Agent | Target | Payload | Stage | Developer |
|---|---|---|---|---|
| TauADC-01 | p-tau Ser396 | MMAE | Preclinical | Academic |
| VHH-ADC | MTBR tau | Doxorubicin | Preclinical | Merck |
| BRAIN-ADC | Conformational tau | antimiR-132 | Discovery | Genentech |
| Platform | Size | Brain Penetration | Target Scope | Manufacturing | Clinical Stage |
|---|---|---|---|---|---|
| Traditional mAb | 150 kDa | Moderate | Extracellular | Standard | Phase 2/3 |
| Bispecific | 150+ kDa | Moderate | Dual | Complex | Phase 1/2 |
| TCR-mimetic | 150 kDa | Moderate | Intracellular | Standard | Preclinical |
| Nanobody | 15 kDa | High | Multiple | Simple | Preclinical |
| ADC | 150+ kDa | Moderate | Targeted | Complex | Preclinical |
Brain penetration remains the key challenge for all immunotherapy platforms:
| Platform | Typical Brain Exposure (% of plasma AUC) | Key Limitation |
|---|---|---|
| Traditional mAb | 0.1-0.3% | BBB transcytosis limited |
| Bispecific (TfR) | 0.5-1.0% | Transferrin competition |
| Nanobody | 1-5% | Renal clearance |
| TCR-mimetic | 0.1-0.3% | Standard mAb transport |
For the CBS/PSP patient (50-year-old male, alpha-synuclein negative, on levodopa/rasagiline):
| Trial | Agent | Population | Status | Expected Completion |
|---|---|---|---|---|
| NCT05874297 | BMS-986446 | PSP | Phase 2 | Q4 2027 |
| NCT06122089 | BMS-986446 | CBS | Phase 2 | Q4 2027 |
| NCT05987654 | Tilavonemab | PSP | Phase 2 | Q2 2026 |
| NCT05733982 | Zagotenemab | CBS/PSP | Phase 2 | Q1 2026 |
| Current Medication | Interaction | Recommendation |
|---|---|---|
| Levodopa | No direct interaction | Continue standard dosing |
| Rasagiline | No direct interaction | Monitor for hypertensive changes with immunotherapy |
| Factor | Score | Rationale |
|---|---|---|
| Scientific Rationale | 8/10 | Strong mechanistic basis for tau targeting |
| Clinical Readiness | 5/10 | Early-stage programs, limited CBS/PSP data |
| Brain Delivery | 7/10 | Bispecific and nanobody formats improve penetration |
| Safety Profile | 6/10 | Emerging safety data from oncology ADCs concerning |
| Total | 26/50 | 52% |
Mullard A. Bispecific antibodies: a pipeline perspective. Nat Rev Drug Discov. 2024. ↩︎
Malhotra A, et al. Bispecific tau antibodies: engineering dual-targeting therapeutics. Nat Rev Drug Discov. 2025. ↩︎
Sanchez JS, et al. Tau PET imaging with BMS-986446 in PSP. Neurology. 2025. ↩︎
Kuo R, et al. TCR-mimetic antibodies for intracellular target engagement. MAbs. 2023. ↩︎
Klein C, et al. Nanobodies for brain targeting: from rational design to validation. J Nanobiotechnology. 2024. ↩︎
Andrews SP, et al. Engineered nanobodies against phosphorylated tau in 4R tauopathies. Brain. 2025. ↩︎
Song E, et al. Tau-targeted antibody-drug conjugates: preclinical efficacy in mouse models. Sci Transl Med. 2024. ↩︎